Haemolytic uraemic syndrome after living-donor liver transplantation: Is small-for-size graft a potential risk factor?

Journal of International Medical Research

Volumn 36, Issue 3, 2008, Pages 599-604

  Luo, J ^a   Zhang, A ^a   Huang, He ^a   Zheng, S ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Calcineurin inhibitors; Haemolytic uraemic syndrome; Liver transplantation; Small for size graft; Small for size syndrome; Tacrolimus

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINUCLEAR ANTIBODY; BASILIXIMAB; BILIRUBIN; CREATININE; DOPAMINE; FLUCONAZOLE; GANCICLOVIR; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MITOCHONDRION ANTIBODY; MOXIFLOXACIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NIFEDIPINE; OCTREOTIDE; PANTOPRAZOLE; SMOOTH MUSCLE ANTIBODY; TACROLIMUS;

ADULT; ANEMIA; ARTICLE; ASCITES; AUTOIMMUNE HEPATITIS; B SCAN; CASE REPORT; CHOLESTASIS; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG MONITORING; DRUG WITHDRAWAL; ESOPHAGUS VARICES BLEEDING; FEMALE; GRAFT DYSFUNCTION; HEMOLYTIC UREMIC SYNDROME; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; KIDNEY FAILURE; LABORATORY TEST; LIVER ATROPHY; LIVER FAILURE; LIVER FUNCTION TEST; LIVER GRAFT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LIVING DONOR; MULTIPLE ORGAN FAILURE; PLASMAPHERESIS; PORTAL HYPERTENSION; POSTOPERATIVE INFECTION; POSTOPERATIVE PERIOD; PROTHROMBIN TIME; RISK FACTOR; SMALL FOR SIZE SYNDROME;

EID: 45149131153     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000803600328     Document Type: Article

References (30)

1. Tarr PI, Gordon CA, Chandler WL: Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005; 365: 1073-1086.
2. Singh N, Gayowski T, Marino IR: Hemolytic uremic syndrome in solid-organ transplant recipients. Transpl Int 1996: 9: 68-75.
3. Lin CC, King KL, Chao YW, et al: Tacrolimus-associated hemolytic uremic syndrome: a case analysis. J Nephrol 2003; 16: 580-585.
4. Trimarchi HM, Truong LD, Brennan S, et al: FK506-associated thrombotic microangiopathy: report of two cases and review of the literature. Transplantation 1999; 67: 539-544.
5. Holman MJ, Gonwa TA, Cooper B, et al: FK506-associated thrombotic thrombocytopenic purpura. Transplantation 1993; 55: 205-206.
6. Much-Pascual S, Samii K, Beris P: Microangiopathic hemolytic anemia complicating FK506 (tacrolimus) therapy. Am J Hematol 1996; 52: 310-312.
7. Rerolle IP, Akposso K, Lerolle N, et al: Tacrolimus-induced hemolytic uremic syndrome and end-stage renal failure after liver transplantation. Clin Transplant 2000; 14: 262-265.
8. Grupp C, Schmidt F, Braun F, et al: Haemolytic uraemic syndrome (HUS) during treatment with cyclosporin A after renal transplantation - is tacrolimus the answer? Nephrol Dial Transplant 1998; 13: 1629-1631.
9. Shulman H, Striker G, Deeg HJ: Nephrotoxicity of cyclosporin A after allogenic bone marrow transplantation. N Engl J Med 1981: 305: 1392-1395.
10. Banerjee D, Kupin W, Roth D: Hemolytic uremic syndrome after multivisceral transplantation treated with intravenous immunoglobulin. J Nephrol 2003; 16: 733-735.
11. Akamatsu N, Sugawara Y, Tamura S, et al: Late mortality from thrombotic microangiopathy after liver transplantation: report of a case. Surg Today 2007; 37: 345-348.
12. Tanabe K, Tokumoto T, Ishida H, et al: Prospective analysis of thrombotic microangiopathy after renal transplantation: comparison between cyclosporine and tacrolimus immunosuppression. Transplant Proc 2002; 34: 1819-1820.
13. Ruggenenti P: Post-transplant hemolytic-uremic syndrome. Kidney Int 2002; 62: 1093-1104.
14. Ramasubbu K, Mullick T, Koo A, et al: Thrombotic microangiopathy and cytomegolovirus in liver transplant recipients: a case-based review. Transpl Infect Dis 2003; 5: 98-103.
15. Murer L, Zacchello G, Bianchi D, et al: Thrombotic microangiopathy associated with parvovirus B 19 infection after renal transplantation. J Am Soc Nephrol 2000; 11: 1132-1137.
16. Remuzzi G, Ruggenenti P, Colledan M, et al: Hemolytic uremic syndrome: a fatal outcome after kidney and liver transplantation performed to correct factor h gene mutation. Am J Transplant 2005; 5: 1146-1150.
17. Zipfel PF, Skerka C: Complement factor H and related proteins: an expanding family of complement-regulatory proteins? Immunol Today 1994; 15: 121-126.
18. Tanaka K, Ogura Y: "Small-for-size graft" and "small-for-size syndrome" in living donor liver transplantation. Yonsei Med J 2004; 45: 1089-1094.
19. Marcos A: Right-lobe living donor liver transplantation: a review. Liver Transpl 2000; 6(6 suppl 2): s59-s63.
20. Suehiro T, Shimada M, Kishikawa K, et al: Effect of introportal infusion to improve small for size graft injury in living donor adult liver transplantation. Transpl Int 2005; 18: 923-928.
21. Shinohora H, Shimada M, Ogasawara T, et al: Pharmacokinetics of cyclosporine A after massive hepatectomy: a hint for small-for-size graft in living donor liver transplantation. Dig Dis Sci 2007; 52: 2490-2496.
22. Kishino S, Ohno K, Shimamura T, et al: A nomogram for predicting the optimal oral dosage of tacrolimus in liver transplant recipients with small-for-size grafts. Clin Transplant 2006; 20: 443-449.
23. Kishino S, Ogawa M, Takekuma Y, et al: The variability of liver graft function and urinary 6β-hydroxycortisol to cortisol ratio during liver regeneration in liver transplant recipients. Clin Transplant 2004; 18: 124-129.
24. Fukatsu S, Yano I, Igarashi T, et al: Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation. Eur J Clin Pharmacol 2001; 57: 479-484.
25. Sugawara Y, Makuuchi M, Kaneko J, et al: Correlation between optimal tacrolimus doses and the graft weight in living donor liver transplantation. Clin Transplant 2002; 16: 102-106.
26. Trotter JF, Stolpman N, Wachs M, et al: Living donor liver transplant recipients achieve relatively higher immunosuppressant blood levels than cadaveric recipients. Liver Transplant 2002; 8: 212-218.
27. Fredericks S, Holt DW, MacPhee IA: The pharmacogenetics of immunosuppression for organ transplantation: a route to individualization of drug administration. Am J Pharmacogenomics 2003; 3: 291-301.
28. Evans WE, Relling MV: Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286: 487-491.
29. Fukudo M, Yano I, Masuda S, et al: Pharmacodynamic analysis of tacrolimus and cyclosporine in living-donor liver transplant patients. Clin Pharmacol Ther 2005; 78: 168-181.
30. Yu S, Wu L, Jin J, et al: Influence of CYP3AS gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation. Transplantation 2006; 81: 46-51.